Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Profiles of prostate cancer cell lines
PubMed Full text in PMC Similar studies
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Heterogeneity of Androgen Receptor Splice Variant-7 (AR-V7) Protein Expression and Response to Therapy in Castration Resistant Prostate Cancer (CRPC)
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines [RNA-seq]
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines [ChIP-seq]
PubMed Full text in PMC Similar studies SRA Run Selector
Role of androgen receptor splice variant 7 (AR-v7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in androgen deprivation conditions [ChIP-Seq]
Activation of P-TEFb by enhancer RNAs associated with lethal prostate cancer [ChIP-seq]
Activation of the P-TEFb Complex by Lethal Prostate Cancer-Associated Enhancer RNAs
Activation of the P-TEFb Complex by Lethal Prostate Cancer-Associated Enhancer RNAs [ChIP-Seq]
Activation of the P-TEFb Complex by Lethal Prostate Cancer-Associated Enhancer RNAs [RNA-Seq]
Identification and characterization of androgen receptor splice variants preferred bindings that drive prostate cancer progression
Identification and characterization of androgen receptor splice variants preferred bindings that drive prostate cancer progression [ChIP-seq]
Identification and characterization of androgen receptor splice variants preferred bindings that drive prostate cancer progression [RNA-seq]
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
PubMed Similar studies Analyze with GEO2R
AR-V7 Targets in Castration-Resistant Prostate Cancer (CRPC) Cell Line
PubMed Full text in PMC Similar studies Analyze with GEO2R
Effects of novel antiandrogens (enzalutamide and ARN-509) on global gene expression in castration-resistant prostate cancer (CRPC) xenograft model
PubMed Similar studies Analyze with GEO2RSRA Run Selector
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on